Inspire Investing LLC Decreases Position in DaVita Inc. (NYSE:DVA)

Inspire Investing LLC lessened its holdings in shares of DaVita Inc. (NYSE:DVA) by 13.1% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 5,608 shares of the company’s stock after selling 844 shares during the quarter. Inspire Investing LLC’s holdings in DaVita were worth $777,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Blue Trust Inc. increased its position in shares of DaVita by 58.6% in the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after acquiring an additional 78 shares during the period. Newbridge Financial Services Group Inc. acquired a new position in shares of DaVita in the 4th quarter valued at $30,000. Family Firm Inc. acquired a new position in shares of DaVita in the 2nd quarter valued at $43,000. Versant Capital Management Inc increased its position in shares of DaVita by 90.6% in the 2nd quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock valued at $45,000 after acquiring an additional 155 shares during the period. Finally, Friedenthal Financial acquired a new position in shares of DaVita in the 2nd quarter valued at $48,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on DVA shares. StockNews.com downgraded DaVita from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 8th. TD Cowen increased their price target on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. Truist Financial increased their price target on DaVita from $150.00 to $165.00 and gave the stock a “hold” rating in a research report on Tuesday, August 20th. Bank of America increased their price target on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 7th. Finally, UBS Group increased their price target on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $157.00.

Insider Activity

In other news, CEO Javier Rodriguez sold 50,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the sale, the chief executive officer now directly owns 837,835 shares in the company, valued at approximately $138,284,666.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CFO Joel Ackerman sold 64,029 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total value of $9,928,336.74. Following the transaction, the chief financial officer now directly owns 111,481 shares of the company’s stock, valued at approximately $17,286,243.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Javier Rodriguez sold 50,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the transaction, the chief executive officer now directly owns 837,835 shares in the company, valued at $138,284,666.75. The disclosure for this sale can be found here. Insiders have sold 173,482 shares of company stock worth $27,387,069 in the last ninety days. Company insiders own 2.00% of the company’s stock.

DaVita Price Performance

NYSE:DVA opened at $164.00 on Friday. DaVita Inc. has a 52 week low of $71.51 and a 52 week high of $166.04. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94. The stock has a market capitalization of $14.38 billion, a PE ratio of 18.64, a price-to-earnings-growth ratio of 0.95 and a beta of 0.87. The stock’s 50-day moving average price is $147.19 and its 200-day moving average price is $140.85.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.47 by $0.12. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The firm had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.15 billion. During the same period last year, the firm earned $2.08 EPS. The company’s quarterly revenue was up 6.2% on a year-over-year basis. As a group, equities analysts expect that DaVita Inc. will post 9.99 EPS for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.